Cargando…

Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting

AIMS: To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) in the real-life setting and to compare incidence of ocular serious adverse events (SAE) after injections administered by nurses and physicians...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kataja, Maria, Hujanen, Pekko, Huhtala, Heini, Kaarniranta, Kai, Tuulonen, Anja, Uusitalo-Jarvinen, Hannele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047152/ https://www.ncbi.nlm.nih.gov/pubmed/29074495 http://dx.doi.org/10.1136/bjophthalmol-2017-311055

Ejemplares similares

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration
por: Heloterä, Hanna, et al.
Publicado: (2022)

Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting
por: Matsubara, Hisashi, et al.
Publicado: (2022)

Oxidative Stress, Hypoxia, and Autophagy in the Neovascular Processes of Age-Related Macular Degeneration
por: Blasiak, Janusz, et al.
Publicado: (2014)

Dysregulated Tear Film Proteins in Macular Edema Due to the Neovascular Age-Related Macular Degeneration Are Involved in the Regulation of Protein Clearance, Inflammation, and Neovascularization
por: Winiarczyk, Mateusz, et al.
Publicado: (2021)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema, Muhammad Raza, et al.
Publicado: (2021)

Expression of VEGFA‐regulating miRNAs and mortality in wet AMD
por: Blasiak, Janusz, et al.
Publicado: (2019)

Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
por: Hussain, Rehan M, et al.
Publicado: (2021)

Choroidal endothelial and macrophage gene expression in atrophic and neovascular macular degeneration
por: Voigt, Andrew P, et al.
Publicado: (2022)

Lack of R-Ras Leads to Increased Vascular Permeability in Ischemic Retinopathy
por: Vähätupa, Maria, et al.
Publicado: (2016)

Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
por: Upasani, Deepa, et al.
Publicado: (2021)

Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2022)

Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment
por: Moon, Bo-Hyun, et al.
Publicado: (2023)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat, Davis, et al.
Publicado: (2020)

Profiling neovascular age‐related macular degeneration choroidal neovascularization lesion response to anti‐vascular endothelial growth factor therapy using SSOCTA
por: Told, Reinhard, et al.
Publicado: (2020)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Visual impairment due to age‐related macular degeneration during 40 years in Finland and the impact of novel therapies
por: Purola, Petri, et al.
Publicado: (2022)

Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration
por: Kaarniranta, Kai, et al.
Publicado: (2020)

Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
por: Sophie, Raafay, et al.
Publicado: (2012)

Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment
por: Mantel, Irmela, et al.
Publicado: (2020)

Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes
por: Mun, Yongseok, et al.
Publicado: (2021)

Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration
por: Dhingra, Narendra, et al.
Publicado: (2022)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands
por: Verbraak, Frank D., et al.
Publicado: (2020)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
por: Moon, Da Ru Chi, et al.
Publicado: (2015)

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials
por: Nguyen, Chu Luan, et al.
Publicado: (2018)

Human Vascular Endothelial Growth Factor A(165) Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration
por: Kokki, Emmi, et al.
Publicado: (2018)

Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
por: Barış, Mine Esen, et al.
Publicado: (2020)

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration
por: Lee, Andy, et al.
Publicado: (2020)

Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration
por: Stattin, Martin, et al.
Publicado: (2020)

Efficacy of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration and Systemic Cardiovascular Risk Factors
por: Łądkowska, Joanna, et al.
Publicado: (2021)

Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis
por: Tuerksever, Cengiz, et al.
Publicado: (2022)

Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: “real life” long-term outcome
por: Beykin, Gala, et al.
Publicado: (2015)

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
por: Gohil, Rishma, et al.
Publicado: (2016)

Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration
por: Onwuka, Oluchukwu, et al.
Publicado: (2023)

Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration
por: Lee, Ji Young, et al.
Publicado: (2016)

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Angermann, Reinhard, et al.
Publicado: (2022)

Efficacy and Safety of Anti–Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison
por: Zhang, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7t7ggdeqa5mpf9tjot0of424be